Search

Displaying results 1631 - 1640 of 8010 in total
  1. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

    Mixtures: . - Salbe + NagelsetCategories: Antifungals for Topical Use, Antifungals for Dermatological Use
  2. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same … Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have

    Categories: MATE 2-K Inhibitors
  4. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  5. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  6. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks.

  7. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    [L39496] IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a process that significantly extends their half-life by evading lysosomal degradation via binding with … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

  8. Drug

    Etafedrine

    go.drugbank.com/drugs/DB11587
    Approved

    It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563]. … Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568].

  9. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.

  10. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics